For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a metabolically stabilized analog of tuftsin. It is approved in Russia since 2009 as an intranasal anxiolytic for GAD and neurasthenia. The pivotal clinical study (Zozulya et al., 2008, n=62) compared Selank to medazepam and found comparable anxiolytic efficacy with additional antiasthenic and psychostimulant effects. All human clinical data comes from Russian institutions; no GCP-compliant international trials exist.
Selank occupies an unusual position in the evidence landscape: it has genuine regulatory approval (Russia, 2009) based on completed clinical trials, 30+ years of research from the Institute of Molecular Genetics, and a well-characterized pharmacological profile. It is not a compound where all evidence is animal models or extrapolation. For the nootropic/anxiolytic peptide category, this puts it in a distinct tier above compounds with no human data at all.
The critical limitation that every reader should understand before interpreting the clinical evidence: all human trials were conducted in Russia, published in Russian-language journals, by research groups affiliated with the same institutions that developed the compound. The pivotal trial (Zozulya et al., 2008) was published in Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova, a Russian-language journal. No GCP-compliant RCT has been conducted or published outside Russia. No regulatory authority other than Russia's Ministry of Health has reviewed the clinical data. The trial sizes (n=62 in the pivotal study) are modest by modern regulatory standards, and no published placebo-controlled trial exists; the comparator was medazepam.
These limitations do not render the Russian evidence worthless, but they do mean it cannot be taken at the same confidence level as a Western Phase 3 trial. Readers should weigh the regulatory approval and the clinical signal while recognizing that the full trial package has not been independently reviewed by FDA, EMA, or any other major regulatory authority. The lack of independent international replication after 15+ years of market availability in Russia is a fact worth noting.
Selank was developed in the late 1970s through the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the Zakusov Scientific Research Institute of Pharmacology, led by N.F. Myasoedov and I.P. Ashmarin. The design rationale was to create a metabolically stable CNS-active peptide from a naturally occurring immunomodulatory sequence. Tuftsin (Thr-Lys-Pro-Arg), the four-amino acid C-terminal fragment of the Fc region of IgG heavy chains, showed preliminary CNS activity but had poor metabolic stability in vivo. Selank adds three amino acids (Pro-Gly-Pro) to the C-terminus of tuftsin, dramatically improving stability and extending duration of action in brain tissue.
The Pro-Gly-Pro extension is not arbitrary: the glyproline tripeptide (Pro-Gly-Pro) is itself bioactive, appearing in the structure of several endogenous neuropeptides and contributing to CNS penetration and enzyme resistance. This design approach produced a compound with both the immunomodulatory properties of tuftsin and a new CNS pharmacological profile centered on anxiolytic activity.
Selank passed full preclinical development in the late 1990s and underwent clinical trials in Russia in the 2000s. The Russian Ministry of Health approved it in 2009 as the pharmaceutical preparation 'Selank 0.15%' intranasal drops, indicated for GAD and neurasthenia in adults. It remains a prescription drug in Russia and Ukraine, marketed under the trade name Selanc, and is dispensed through pharmacies in those countries.
Selank's mechanism of action is multi-target and not fully resolved despite decades of research. The leading hypothesis centers on indirect GABAergic potentiation: Selank does not bind directly to GABAA receptor benzodiazepine sites but appears to modulate GABAergic neurotransmission allosterically and via gene expression changes. Volkova et al. (2016, Frontiers in Pharmacology) showed that intranasal Selank alters the mRNA levels of multiple genes involved in GABAergic neurotransmission in rat frontal cortex, with expression changes overlapping with, but distinct from, those induced by direct GABA administration. Kasian et al. (2017) provided additional evidence that Selank acts as an allosteric modulator of GABAA receptor function, amplifying the anxiolytic effects of diazepam when co-administered.
Enkephalin degradation inhibition is a second well-documented mechanism. Kost et al. (2001, Bioorganicheskaya Khimiya) showed that both Selank and Semax inhibit the enkephalin-degrading enzymes in human serum (carboxypeptidase H and phenylmethylsulfonylfluoride-inhibited carboxypeptidase), increasing the half-life of endogenous leu-enkephalin and met-enkephalin. The clinical relevance was demonstrated by Zozulya et al. (2008): patients with GAD had significantly reduced tau(1/2) leu-enkephalin levels at baseline, and Selank treatment partly restored these to normal, with the degree of restoration correlating with clinical anxiety reduction.
Monoamine modulation represents a third mechanism. Narkevich et al. (2008) showed dose-dependent changes in noradrenaline, dopamine, serotonin, and their metabolites in rat hippocampus, hypothalamus, and frontal cortex after Selank (300 mcg/kg). Selank reduces serotonin metabolism in key brain regions (Semenova et al., 2009), which may contribute to its non-sedating profile: unlike SSRIs that increase synaptic serotonin acutely, Selank appears to normalize rather than elevate serotonin flux.
BDNF upregulation has been documented as a fourth mechanism. Inozemtseva et al. (2008) showed that intranasal Selank (50 mcg/kg) increased BDNF mRNA expression by 1.4-fold and TrkB tyrosine phosphorylation by 1.6-fold in rat hippocampus. This BDNF upregulation is consistent with the nootropic (learning and memory-enhancing) effects observed in rodent studies and may explain the antiasthenic (energy-restoring) effects reported in clinical trials.
Immunomodulatory activity, retained from parent tuftsin, includes modulation of IL-6 expression, upregulation of anti-inflammatory cytokines (IL-4), and enhancement of phagocytic activity. In GAD patients, Selank treatment altered the Th1/Th2 cytokine balance toward a more anti-inflammatory profile, suggesting neuroimmune interactions contribute to its clinical effects.
Zozulya et al. (2008) is the primary human evidence for Selank's anxiolytic efficacy. In 62 patients with GAD or neurasthenia, intranasal Selank (2,700 mcg/day for 14 days, delivered as the approved 0.15% formulation) produced anxiolytic effects comparable to medazepam (30 mg/day) on HARS, Zung, and CGI scales. Selank additionally showed antiasthenic effects (reduced fatigue and psycho-physical exhaustion) and psychostimulant properties not seen with medazepam, a finding the authors attributed to nootropic and BDNF-related effects rather than anxiolytic action alone. No sedation, muscle relaxation, or withdrawal was observed with Selank.
A secondary finding of mechanistic interest: GAD patients had significantly decreased baseline tau(1/2) leu-enkephalin (a measure of how long leu-enkephalin survives degradation in serum). Selank treatment partly restored this parameter in GAD patients, and the degree of restoration correlated with clinical anxiety reduction. This provided in-human validation of the enkephalin degradation inhibition mechanism.
The pharmaco-EEG study (Neznamov et al., 2012) in 20 patients documented heterogeneous response profiles: 40% were rapid responders showing HARS reduction from 20.3 to 7.0 within 3 days, associated with measurable EEG changes (increased beta rhythm, decreased theta and low-frequency alpha) after a single 900 mcg dose. The remaining 60% responded gradually over 14 days. Both groups achieved clinically significant anxiety reduction by day 14.
The controlled trial data for GAD represents the strongest clinical evidence in this profile, but must be interpreted with the caveat that it is a single trial from a Russian institution, published in a Russian-language journal, with medazepam (not placebo) as comparator. The lack of a placebo arm means the absolute magnitude of effect versus natural symptom resolution cannot be determined. The n=30 Selank arm is modest. By the standards required for FDA or EMA approval, this trial package would need to be supplemented with at least one adequately powered, placebo-controlled GCP RCT. Within its limitations, the non-inferiority to medazepam finding is clinically meaningful, and the additional antiasthenic and psychostimulant properties differentiate Selank from standard benzodiazepine treatment.
The entire human clinical evidence base for Selank consists of trials conducted in Russia, by teams affiliated with the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology, the same institutions that developed the compound. The pivotal Zozulya et al. (2008) trial has never been published in an English-language peer-reviewed journal; the available English-language summary comes via PubMed abstract and secondary citations.
No clinical trial for Selank has been registered on ClinicalTrials.gov or EudraCT. No independent academic group outside Russia and Ukraine has published a clinical Selank study. The compound has been commercially available in Russia for 15+ years and has had ample opportunity to attract independent clinical investigation; none has been published.
The absence of placebo arms in the most-cited human trials is a structural limitation: comparing Selank to medazepam at a single dose level over a short period does not allow assessment of placebo effect magnitude. In anxiety disorders, placebo response rates of 30 to 50% are typical in controlled trials, meaning the apparent clinical benefit could reflect a mixture of drug effect and placebo response that cannot be separated without a placebo arm.
This does not mean the Russian evidence is fabricated or that Selank is ineffective. Russia's GOST standards for clinical trials, while not identical to GCP, are not trivial. The regulatory approval reflects genuine review of clinical data. The concern is epistemic: the quality and independence of the evidence cannot be fully assessed by external reviewers without access to full trial reports, and the absence of any independent replication after 15 years is an empirical observation that should temper confidence.
This is a structural limitation of the evidence, not an accusation of misconduct. Selank's Russian regulatory approval reflects real clinical data reviewed by Russian authorities. But the absence of any GCP-compliant trial, any placebo arm, any English-language primary publication, and any independent replication in 15+ years of market availability means the clinical evidence cannot be evaluated at the confidence level that FDA or EMA approval would require. Readers should calibrate their confidence accordingly.
The Kaplan human volunteer study, cited in multiple Russian review papers, reportedly showed that intranasal Selank at 16 mcg/kg significantly improved attention and short-term memory in healthy volunteers on neuropsychological testing. This is one of the few human data points on Selank in non-clinical (non-anxious) populations. The study is cited only in Russian review papers and has not been independently verified by this publication.
The clinical data from Zozulya et al. (2008) showed that Selank-treated patients reported antiasthenic (reduced fatigue) and psychostimulant effects not seen with the benzodiazepine comparator, suggesting a nootropic dimension that distinguishes Selank pharmacologically from classical anxiolytics.
Preclinical rodent studies consistently show improvements in learning and memory across multiple paradigms (spatial memory, passive avoidance, operant conditioning) after Selank administration. The BDNF upregulation (1.4-fold in hippocampus, Inozemtseva et al., 2008) provides a plausible biological substrate for these effects.
The nootropic effects have support from human volunteer data (single Russian study, not fully accessible in English), clinical reports of antiasthenic effects in GAD patients, and consistent rodent data. The evidence is more indirect than the anxiolytic evidence. The BDNF upregulation mechanism is credible. The combination of anxiety reduction and cognitive enhancement, without sedation, is the pharmacologically distinguishing feature of Selank compared to benzodiazepines.
Selank retains tuftsin's immunomodulatory properties and adds new ones. In patients with anxiety-asthenic disorders (Uchakina et al., 2008), 14 days of Selank administration altered the Th1/Th2 cytokine balance toward a more anti-inflammatory profile, with changes in IL-6 expression and T-helper cell ratios. This suggests that Selank's clinical benefit in anxiety may partly operate through a neuroimmune mechanism, not just through direct neurotransmitter modulation.
In animal models, Selank demonstrated antiviral activity in an influenza model (Ershov et al., 2009), consistent with its tuftsin-derived phagocyte-enhancing properties. Kasian et al. (2017) documented that stressed rats treated with Selank showed reduced pro-inflammatory cytokines (IL-1beta, IL-6, TGF-beta1) and restored anti-inflammatory IL-4, suggesting a stress-protective immunological effect.
The immunomodulatory properties have not been developed clinically beyond anxiety-associated conditions. No immune-primary indication has been pursued through clinical development.
Immunomodulatory properties are well-documented in animals and in a small human study in anxiety-asthenic patients. The mechanism is biologically plausible given tuftsin's established immune role. These properties may contribute to Selank's anti-inflammatory, anti-stress profile in clinical use. No dedicated immunological indication has been pursued, and the human data on immune endpoints is limited to one Russian study.
Kasian et al. (2017) demonstrated in rats under chronic unpredictable mild stress conditions that combined Selank plus diazepam was the most effective anxiolytic combination, more effective than either agent alone. Selank administered alone was the most effective at reducing anxiety induced by the course of substance administration itself (in non-stressed conditions), while the combination dominated under chronic stress. The study authors concluded that Selank's GABAergic allosteric modulation may increase diazepam's affinity at GABAA receptors, amplifying its effect and potentially allowing dose reduction.
A clinical study in approximately 70 anxiety disorder patients reportedly compared oral phenazepam alone versus oral phenazepam combined with intranasal Selank. The combination reportedly produced better anxiolytic efficacy and reduced the side effects of phenazepam (sedation, muscle relaxation). This finding has significant practical implications: if validated, Selank could serve as a benzodiazepine-sparing adjunct, allowing lower benzodiazepine doses for equivalent efficacy while reducing dependence risk. The primary publication is in Russian and has not been independently verified.
The benzodiazepine potentiation finding is mechanistically coherent with Selank's allosteric GABAergic modulation, and the rat UCMS data is high quality and recently published in an international journal. The human clinical data (phenazepam combination study) is cited but the primary publication is in Russian. If this finding is replicable, it represents a clinically important application distinct from Selank's standalone anxiolytic use. The combination should theoretically be used with caution until human safety data clarifies the interaction risk profile at higher benzodiazepine doses.
Russian-approved anxiolytic. 200-600mcg daily sub-Q or intranasal.
Selank has the strongest clinical evidence base of any research peptide outside formal FDA/EMA approval programs, by virtue of Russian regulatory approval and 15+ years of clinical use. The intranasal route is supported by the human trial data; subcutaneous injection is used in research communities but has not been formally studied in clinical populations. The approved Russian dose of 900 mcg three times daily (2,700 mcg/day) is higher than many community protocols, which often use 250 to 500 mcg daily via subcutaneous injection. The comparability of subcutaneous and intranasal PK in humans has not been formally published, though both routes have been used in preclinical studies. For intranasal use, the 0.15% concentration means each drop delivers approximately 75 mcg; 2 drops per nostril per administration is the approved regimen. N-Acetyl Selank Amidate is a chemically modified analog with no clinical trial data of its own.
Selank is the anxiety-specific counterpart to Semax (profile #11), which emphasizes neuroprotection and cognitive enhancement. Both emerged from the same Russian Institute of Molecular Genetics program, share the glyproline extension design, and are approved as nasal drops in Russia. The key pharmacological distinction: Semax is ACTH-derived and primarily nootropic-neuroprotective; Selank is tuftsin-derived and primarily anxiolytic. In practice, Semax has a slightly more stimulating quality while Selank has a calming quality without sedation. Among anxiolytic compounds reviewed in this series, Selank has the strongest human evidence (one active-comparator trial, Russian regulatory approval) and the best established safety record. GLP-1 peptides (Semaglutide, Tirzepatide) have dramatically stronger evidence but operate in an entirely different pharmacological and indication space. The closest comparison within the nootropic category is Cerebrolysin (profile #13), which has Tier 1-2 evidence in vascular dementia but in a completely different indication.
Selank has the most robust human safety data of any research peptide available outside of formally FDA-approved compounds, by virtue of its 15+ years of prescription use in Russia. The safety profile from clinical trials and post-marketing experience in Russia is favorable.
In the pivotal trial (Zozulya et al., 2008, n=62, 14-day intranasal course), Selank was well tolerated with no serious adverse events reported. No sedation, muscle relaxation, amnesia, or withdrawal syndrome were observed, which are the characteristic adverse effects of benzodiazepine comparators. Tolerance and dependence were not observed in clinical studies or in the 15+ year post-marketing period in Russia.
The most commonly reported adverse effect from intranasal administration is transient nasal mucosal irritation and mild discomfort, consistent with intranasal delivery of peptide solutions generally. Some case reports note mild nasal cavity discoloration (in a minority of patients, approximately 10%) with prolonged intranasal use.
Important limitations on safety conclusions: the Russian clinical safety database, while meaningful, does not meet the standards of a formal ICH E1 safety database required for approval in Western regulatory jurisdictions. Long-term safety data beyond 14-day course use has not been systematically published. Selank's immunomodulatory properties (IL-6 modulation, Th1/Th2 balance changes) have not been evaluated for safety in immunocompromised individuals or those with autoimmune conditions. No reproductive toxicology or teratogenicity data in humans has been published. Selank should not be used in pregnancy or breastfeeding given the absence of safety data in these populations.
Selank stands apart from almost every research peptide in this series by having genuine regulatory approval in a major country (Russia, 2009) based on completed clinical trials. The pivotal study (Zozulya et al., 2008, n=62) showed non-inferiority to medazepam for GAD with a cleaner side effect profile, and the compound has been dispensed by prescription in Russian and Ukrainian pharmacies for 15+ years without major safety signals emerging. This is not theoretical efficacy: it is a drug that has been used clinically.
The honest accounting of limitations is equally important. The entire human evidence base is Russian, from the compound's developers, published in Russian-language journals, with no placebo arms in the key trials and no international GCP-compliant replication. No Western regulatory authority has reviewed the clinical data. The absence of any independent international trial after 15 years of availability is an empirical fact that cannot be wished away.
The evidence tier of Tier 3 reflects this mixed picture accurately: human data exists, regulatory approval in one jurisdiction was achieved, but the evidence does not meet the standards required for confidence-level assessments that FDA or EMA approvals would provide. For a researcher evaluating Selank's anxiolytic potential, the Russian data is meaningful evidence that warrants more weight than animal studies alone. For a clinician in a Western jurisdiction, the absence of GCP validation and placebo control means the evidence must be treated as preliminary.
Among the peptides in this series, Selank has the strongest human anxiolytic evidence and the most established safety record from real-world use. The comparison to benzodiazepines without sedation, dependence, or cognitive impairment is a genuine pharmacological differentiation, not marketing language. Whether that differentiation holds in a properly powered placebo-controlled trial remains to be determined.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use